Sa1093 Inosine Triphosphastase (ITPA) Variants Predict Treatment-Induced Anemia, Ribavirin Dose-Reduction and Need for Erythropoietin Support During Peginterferon/Ribavirin Therapy for Chronic HCV
Clark, P J.; Aghemo, A; Degasperi, E; Galmozzi, E; Thompson, A J.; Patel, K; Rumi, M Grazia; Prati, G.; Colombo, M
Gastroenterology 142(5): S-967-S-968
2012
ISSN/ISBN: 0016-5085
DOI: 10.1016/s0016-5085(12)63746-9
Accession: 064240212
PDF emailed within 0-6 h: $19.90
Related References
Clark, P.J.; Aghemo, A.; Degasperi, E.; Galmozzi, E.; Thompson, A.J.; Patel, K.; Rumi, M.G.; Prati, G.M.; Muir, A.J.; Colombo, M. 2012: Itpa Variants Predict Treatment-Induced Anemia and the Need for Ribavirin Dose Reduction and Erythropoietin Support Journal of Hepatology 56: S432-S433Thompson, A.J.; Fellay, J.; Patel, K.; Tillmann, H.L.; Naggie, S.; Ge, D.; Urban, T.J.; Shianna, K.V.; Muir, A.J.; Fried, M.W.; Afdhal, N.H.; Goldstein, D.B.; McHutchison, J.G. 2010: Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction Gastroenterology 139(4): 1181-1189
Eskesen, A.N.ør.; Melum, E.; Moghaddam, A.; Bjøro, K.; Verbaan, H.; Ring-Larsen, H.; Dalgard, O. 2012: Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort European Journal of Gastroenterology and Hepatology 24(8): 890-896
Tseng, K.-C.; Chen, L.-H.; Chen, C.-Y.; Chang, T.-T.; Chou, A.-L.; Wu, I.-C.; Cheng, P.-N. 2009: Low dose erythropoietin-beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon Alfa-2b Hepatology Research: the Official Journal of the Japan Society of Hepatology 39(6): 539-545
Akamatsu, S.; Hayes, C.N.; Tsuge, M.; Murakami, E.; Hiraga, N.; Abe, H.; Miki, D.; Imamura, M.; Ochi, H.; Chayama, K.; Aimitsu, S.; Aisaka, Y.; Amano, H.; Amimoto, T.; Arataki, K.; Asada, N.; Azakami, T.; Ishida, K.; Ishihara, H.; Ishitobi, T.; Ito, H.; Kamada, K.; Kamiyasu, M.; Kawakami, H.; Kira, S.; Kitamoto, M.; Kodama, H.; Kohno, H.; Kohno, H.; Masanaga, T.; Miura, T.; Mori, N.; Moriya, T.; Nabeshima, Y.; Nagaoki, Y.; Nakamura, T.; Nakanishi, T.; Nakashio, R.; Nonaka, M.; Ohbayashi, M.; Takaki, S.; Takesaki, E.; Tamura, T.; Tsuji, K.; Waki, K.; Watanabe, 2015: Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism Journal of Viral Hepatitis 22(2): 166-174
Hadziyannis, S.J.; Sette, H.; Morgan, T.R.; Balan, V.; Diago, M.; Marcellin, P.; Ramadori, G.; Bodenheimer, H.; Bernstein, D.; Rizzetto, M.; Zeuzem, S.; Pockros, P.J.; Lin, A.; Ackrill, A.M. 2004: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Annals of Internal Medicine 140(5): 346-355
Murakawa, M.; Asahina, Y.; Nagata, H.; Nakagawa, M.; Kakinuma, S.; Nitta, S.; Kawai-Kitahata, F.; Otani, S.; Kaneko, S.; Miyoshi, M.; Tsunoda, T.; Asano, Y.; Sato, A.; Itsui, Y.; Azuma, S.; Nouchi, T.; Furumoto, Y.; Asano, T.; Chuganji, Y.; Tohda, S.; Watanabe, M. 2017: ITPA gene variation and ribavirin-induced anemia in patients with genotype 2 chronic hepatitis C treated with sofosbuvir plus ribavirin Hepatology Research: the Official Journal of the Japan Society of Hepatology 47(11): 1212-1218
Azakami, T.; Hayes, C.N.; Sezaki, H.; Kobayashi, M.; Akuta, N.; Suzuki, F.; Kumada, H.; Abe, H.; Miki, D.; Tsuge, M.; Imamura, M.; Kawakami, Y.; Takahashi, S.; Ochi, H.; Nakamura, Y.; Kamatani, N.; Chayama, K. 2011: Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy Journal of Medical Virology 83(6): 1048-1057
Takaki, S.; Tsubota, A.; Hosaka, T.; Akuta, N.; Someya, T.; Kobayashi, M.; Suzuki, F.; Suzuki, Y.; Saitoh, S.; Arase, Y.; Ikeda, K.; Kumada, H. 2004: Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C Journal of Gastroenterology 39(7): 668-673
Holmes, J.A.; Roberts, S.K.; Ali, R.J.; Dore, G.J.; Sievert, W.; McCaughan, G.W.; Crawford, D.H.; Cheng, W.S.; Weltman, M.D.; Bonanzinga, S.; Visvanathan, K.; Sundararajan, V.; Desmond, P.V.; Bowden, D.Scott.; Matthews, G.V.; Thompson, A.J. 2014: ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response Hepatology 59(6): 2152-2160
Milazzo, L.; Landonio, S.; Magni, C.; Gervasoni, C.; Calvi, E.; Cheli, S.; Clementi, E.; Galli, M.; Falvella, F.S. 2014: P1168 Itpa And Slc29A1 Genotyping Before Triple Therapy Predict Severity Of Ribavirin-Induced Anemia Journal of Hepatology 60(1): S473-S474
Dai, C-Yen.; Huang, C-Feng.; Chuang, W-Long.; Huang, J-Fu.; Yu, M-Lung. 2009: The substantial role of initial ribavirin dose on the response to peginterferon alpha/ribavirin therapy in patients with genotype 1b chronic hepatitis C American Journal of Gastroenterology 104(9): 2358-2359
Brixner, D.I.; Ye, X.; Chu, T.-C.; Blumentals, W.A.; Hassanein, T.I. 2009: Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists 66(24): 2171-2178
Dore, G.; Knysz, B.; Luo, Y.; Janczewska, E.; Streinu-Cercel, A.; Caruntu, F.A.; Motoc, A.; Mazur, W.; Shaw, D.; Tornai, I.; Sasadeusz, J.; Skoien, R.; Sullivan, D.; Liu, X.; Podsadecki, T. 2015: P0847 : Malachite-Ii: Phase 3b trial of ombitasvir/paritaprevir/r and dasabuvir + ribavirin or telaprevir + peginterferon/ribavirin in peginterferon/ribavirin treatment-experienced adults with Hcv genotype 1 Journal of Hepatology 62: S656-S657
Dore, G J.; Knysz, B; Luo, Y; Janczewska, E; Streinu-Cercel, A; Caruntu, F A.; Motoc, A; Mazur, W; Shaw, D R.; Tornai, I; Sasadeusz, J; Skoien, R; Sullivan, D; Liu, X; Podsadecki, T 2015: Tu1015 MALACHITE-II: Phase 3b Trial of Ombitasvir/Paritaprevir/R and Dasabuvir + Ribavirin or Telaprevir + Peginterferon/Ribavirin in Peginterferon/Ribavirin Treatment-Experienced Adults With HCV Genotype 1 Gastroenterology 148(4): S-1084-S-1085